Bill Text — Apr 18, 2012
This bill’s text is now available.
GovTrack Insider, our Kickstarter-backed work to summarize bills in Congress, has resumed. Here’s what we’ve been up to:
Apr 18, 2012
112th Congress, 2011–2013
This bill was introduced on April 18, 2012, in a previous session of Congress, but was not enacted.
Representative for Maryland's 8th congressional district
Read Text »
Last Updated: Apr 18, 2012
Length: 2 pages
To permit manufacturers of generic drugs to provide additional warnings with respect to such drugs in the same manner that the Food and Drug Administration allows brand names to do so.
The bill’s title was written by its sponsor.
This is the first step in the legislative process.
This is a House of Representatives bill in the United States Congress (indicated by the “H.R.” in “H.R. 4384”). A bill must be passed by both the House and Senate in identical form and then be signed by the President to become law.
The committee chair determines whether a bill will move past the committee stage.
There have been no roll call votes related to this bill.
Click a format for a citation suggestion:
Civic Impulse. (2016). H.R. 4384 — 112th Congress: Patient Safety and Drug Labeling Improvement Act. Retrieved from https://www.govtrack.us/congress/bills/112/hr4384
“H.R. 4384 — 112th Congress: Patient Safety and Drug Labeling Improvement Act.” www.GovTrack.us. 2012. February 11, 2016 <https://www.govtrack.us/congress/bills/112/hr4384>
|title=H.R. 4384 (112th)
|accessdate=February 11, 2016
|author=112th Congress (2012)
|date=April 18, 2012
|quote=Patient Safety and Drug Labeling Improvement Act